201 related articles for article (PubMed ID: 25135294)
1. Dabigatran excess: case report and review of the literature.
Sarma A; Rossi JE; Connors JM; Giugliano RP
Cardiol Ther; 2013 Jun; 2(1):111-24. PubMed ID: 25135294
[TBL] [Abstract][Full Text] [Related]
2. Supratherapeutic dabigatran: a cause of life-threatening haemorrhage.
Hennessy M; Reidy B; Ní Ainle F; Conneely J; McDermott C; Scanaill PÓ
Anaesth Rep; 2023; 11(1):e12208. PubMed ID: 36632350
[TBL] [Abstract][Full Text] [Related]
3. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
[TBL] [Abstract][Full Text] [Related]
4. Managing the perioperative patient on direct oral anticoagulants.
Leitch J; van Vlymen J
Can J Anaesth; 2017 Jun; 64(6):656-672. PubMed ID: 28429198
[TBL] [Abstract][Full Text] [Related]
5. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
Kumar R; Smith RE; Henry BL
J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report.
Xie D; Wang X; Li Y; Chen R; Zhao Y; Xu C; Zhang Q; Zhang Y
Front Aging Neurosci; 2021; 13():765037. PubMed ID: 34970137
[No Abstract] [Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
[TBL] [Abstract][Full Text] [Related]
8. Who, when, and how to reverse non-vitamin K oral anticoagulants.
Aronis KN; Hylek EM
J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
[TBL] [Abstract][Full Text] [Related]
9. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
10. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
12. [Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?].
Bahrmann P; Christ M
Herz; 2018 May; 43(3):214-221. PubMed ID: 29260237
[TBL] [Abstract][Full Text] [Related]
13. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
Fagundes V; Mesquita M
Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Dabigatran with Idarucizumab.
Sodha NR; Sellke FW
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
[TBL] [Abstract][Full Text] [Related]
16. [Experience with idarucizumab as a reverse agent of dabigatran].
Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran etexilate: what do hospitalists need to know?
Zeidan A; Faltas B; Streiff M
J Hosp Med; 2012 Mar; 7(3):262-9. PubMed ID: 22128108
[TBL] [Abstract][Full Text] [Related]
18. Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Kutner S; Scaturo N; Williams B
Am J Emerg Med; 2021 Aug; 46():800.e1-800.e3. PubMed ID: 33612323
[TBL] [Abstract][Full Text] [Related]
19. New oral anticoagulants: their role and future.
Shapiro S; Laffan M
Clin Med (Lond); 2013 Dec; 13 Suppl 6():s53-7. PubMed ID: 24298185
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
